| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MINIREVIEW |
Dipartimento di Biologia e Patologia Cellulare e Molecolare, University Federico II c/o Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, 80131 Naples, Italy
Address all correspondence and requests for reprints to: Dr. Massimo Santoro, Dipartimento di Biologia e Patologia Cellulare e Molecolare, University Federico II, via S. Pansini 5, 80131 Naples, Italy. E-mail: masantor{at}unina.it.
Abstract
The RET gene encodes a single-pass transmembrane receptor tyrosine kinase. RET is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma. The latter may arise as a component of multiple endocrine neoplasia type 2 syndromes; germline mutations in RET are responsible for multiple endocrine neoplasia type 2 inheritance. In this report we review data on the mechanisms leading to RET oncogenic conversion and on RET targeting as a strategy in thyroid cancer treatment.
This article has been cited by other articles:
 |
|
 |
|
  L Foppiani, F Forzano, I Ceccherini, W Bruno, P Ghiorzo, F Caroli, P Quilici, R Bandelloni, A Arlandini, G Sartini, et al. Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene Eur. J. Endocrinol., March 1, 2008; 158(3): 417 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mariggio, B. M. Filippi, C. Iurisci, L. K. Dragani, V. De Falco, M. Santoro, and D. Corda Cytosolic Phospholipase A2{alpha} Regulates Cell Growth in RET/PTC-Transformed Thyroid Cells Cancer Res., December 15, 2007; 67(24): 11769 - 11778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Allocca, U. Di Vicino, M. Petrillo, F. Carlomagno, L. Domenici, and A. Auricchio Constitutive and AP20187-Induced Ret Activation in Photoreceptors Does Not Protect from Light-Induced Damage Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 5199 - 5206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Heymach, B. E. Johnson, D. Prager, E. Csada, J. Roubec, M. Pesek, I. Spasova, C. P. Belani, I. Bodrogi, S. Gadgeel, et al. Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2007; 25(27): 4270 - 4277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dames, R. L. Margraf, D. C. Pattison, C. T. Wittwer, and K. V. Voelkerding Characterization of Aberrant Melting Peaks in Unlabeled Probe Assays J. Mol. Diagn., July 1, 2007; 9(3): 290 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Krause, S. Karger, A. Schierhorn, S. Poncin, M.-C. Many, and D. Fuhrer Proteomic Profiling of Cold Thyroid Nodules Endocrinology, April 1, 2007; 148(4): 1754 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Knowles, J. Murray-Rust, S. Kjaer, R. P. Scott, S. Hanrahan, M. Santoro, C. F. Ibanez, and N. Q. McDonald Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain J. Biol. Chem., November 3, 2006; 281(44): 33577 - 33587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iervolino, R. Iuliano, F. Trapasso, G. Viglietto, R. M. Melillo, F. Carlomagno, M. Santoro, and A. Fusco The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. Cancer Res., June 15, 2006; 66(12): 6280 - 6287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Niedziela Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr. Relat. Cancer, June 1, 2006; 13(2): 427 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Iavarone, M. Acunzo, F. Carlomagno, A. Catania, R. M. Melillo, S. M. Carlomagno, M. Santoro, and M. Chiariello Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene J. Biol. Chem., April 14, 2006; 281(15): 10567 - 10576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, and M. Santoro BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, March 1, 2006; 98(5): 326 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sawai, Y. Okada, K. Kazanjian, J. Kim, S. Hasan, O. J. Hines, H. A. Reber, D. S.B. Hoon, and G. Eibl The G691S RET Polymorphism Increases Glial Cell Line-Derived Neurotrophic Factor-Induced Pancreatic Cancer Cell Invasion by Amplifying Mitogen-Activated Protein Kinase Signaling Cancer Res., December 15, 2005; 65(24): 11536 - 11544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Xing BRAF mutation in thyroid cancer Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vidal, S. Wells, A. Ryan, and R. Cagan ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma Cancer Res., May 1, 2005; 65(9): 3538 - 3541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Seeman and G. J. Strewler Clinical and Basic Research Papers - December 2004 Selections IBMS BoneKEy, January 1, 2005; 2(1): 1 - 5. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
